Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cf-pharmtech-inc-class-h" target="_blank" data-smartkarma-citation="entities:48966:1" rel="noopener">CF PharmTech (2652 HK)</a> intends to place 22M H Shares at the price of HK$13.82 per share. The placing price represents a discount of ~12% to the undisturbed closing price.</li>
<li>The company intends to apply the net proceeds mainly for clinical and pre-clinical development of its innovative drug candidates and development of its complex inhalation formulation products globally.</li>
<li>On October 8, 2025, CF PharmTech got listed on the HK Stock Exchange. The net proceeds from the Global Offering amounted to ~HK$525M, of which HK$129M had been utilized.</li>
</ul>



CF PharmTech (2652 HK) intends to place 22M H Shares at the price of HK$13.82 per share. The placing price represents a discount of ~12% to the undisturbed closing price.
The company intends to apply the net proceeds mainly for clinical and pre-clinical development of its innovative drug candidates and development of its complex inhalation formulation products globally.
On October 8, 2025, CF PharmTech got listed on the HK Stock Exchange. The net proceeds from the Global Offering amounted to ~HK$525M, of which HK$129M had been utilized.


CF PharmTech (2652 HK) Placement: Raising Fund to Feed R&D Amid Unutilized IPO Proceeds

Thematic (Sector/Industry)

<ul>
<li>Innovent Biologics enters global licensing and collaboration agreement with Pfizer for the R&amp;D of 12 promising breakthrough early-stage and de novo cancer medicines. Total value of the deal is $10.5B.</li>
<li>Olympus has decided to acquire Israel-based medical devices manufacturer BioProtect for $270M. GC Biopharma announced that Eli Lilly is acquiring entire stake of its U.S. affiliate Curevo Vaccine for $1.5B.</li>
<li>Daewoong Pharmaceutical received approval for its type 2 diabetes drug Enblo in Mexico. Dong-A ST announced that MetaVia’s obesity drug candidate DA-1726 demonstrated safety and tolerability in Phase 1 trial.</li>
</ul>


Innovent Biologics enters global licensing and collaboration agreement with Pfizer for the R&amp;D of 12 promising breakthrough early-stage and de novo cancer medicines. Total value of the deal is $10.5B.
Olympus has decided to acquire Israel-based medical devices manufacturer BioProtect for $270M. GC Biopharma announced that Eli Lilly is acquiring entire stake of its U.S. affiliate Curevo Vaccine for $1.5B.
Daewoong Pharmaceutical received approval for its type 2 diabetes drug Enblo in Mexico. Dong-A ST announced that MetaVia’s obesity drug candidate DA-1726 demonstrated safety and tolerability in Phase 1 trial.


APAC Healthcare Weekly (May 31) – Innovent Biologics, Junshi Bio, Henlius Bio, Olympus, GC Bio

China

CF PharmTech is a specialty pharmaceutical company focused on the research, development, manufacturing, and commercialization of inhalation technologies and respiratory drugs. The company specializes in treatments for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis, with key products including budesonide suspension for inhalation and azelastine hydrochloride and fluticasone propionate nasal spray. Headquartered in Suzhou, China, the company was founded in 2007.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CF PharmTech (2652 HK)